Information

Dear user, the application need JavaScript support. Please enable JavaScript in your browser.

Title of the item:

Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.

Title:
Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.
Authors:
Dos Santos MR; Instituto do Coração do Hospital das Clínicas da Universidade de São Paulo (InCor HC-FMUSP), Brazil. Electronic address: .
Source:
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan; Vol. 57 (1), pp. 106176.
Publication Type:
Letter
Language:
English
Imprint Name(s):
Original Publication: Amsterdam : Elsevier Science Publishers, c1991-
MeSH Terms:
COVID-19 Drug Treatment*
Antiviral Agents/*therapeutic use
Azithromycin/*therapeutic use
Hydroxychloroquine/*therapeutic use
SARS-CoV-2/*pathogenicity
Anti-Bacterial Agents/therapeutic use ; Antimalarials/therapeutic use ; COVID-19/virology ; Clinical Trials as Topic ; Drug Combinations ; Drug Repositioning ; Humans ; Uncertainty
References:
ESC Heart Fail. 2018 Jun;5(3):372-375. (PMID: 29460476)
Int J Antimicrob Agents. 2020 Jul;56(1):105949. (PMID: 32205204)
Substance Nomenclature:
0 (Anti-Bacterial Agents)
0 (Antimalarials)
0 (Antiviral Agents)
0 (Drug Combinations)
4QWG6N8QKH (Hydroxychloroquine)
83905-01-5 (Azithromycin)
Entry Date(s):
Date Created: 20210107 Date Completed: 20210114 Latest Revision: 20221207
Update Code:
20240105
PubMed Central ID:
PMC7833570
DOI:
10.1016/j.ijantimicag.2020.106176
PMID:
33408022
Editorial & Opinion

We use cookies to help identify your computer so we can tailor your user experience, track shopping basket contents and remember where you are in the order process.